X

Reset Password

Username:

Change Password

Old Password:
New Password:
We have completed your request.

Reata Pharmaceuticals Closes Class A Common Stock Public Offering

Published: 11-18-2019

Vinson & Elkins advised Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, in its underwritten follow-on public offering of 2,760,000 shares of its Class A common stock, which included 360,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a price to the public of $183.00 per share.

The gross proceeds to Reata from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $505.1 million. The offering closed on November 18, 2019.

The V&E corporate team was led by partners Robert Kimball and Brenda Lenahan with assistance from associates Stancell Haigwood, Grace-Ann Duquette and Breanna Kelly. Partner Wendy Salinas and associate Jacob Wight advised on tax issues.


Lawyer Contacts

+1.214.220.7860
rkimball@velaw.com
+1.212.237.0133
blenahan@velaw.com

Media Contact

Melissa Anderson Senior Communications Manager

T +1.713.758.2030
manderson@velaw.com

Connect with V&E

Stay informed by receiving our e-lerts. Select your preferred communications.